A SWOT analysis of the development of health technology assessment in Iran.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
04
2022
accepted:
14
03
2023
medline:
3
4
2023
entrez:
30
3
2023
pubmed:
31
3
2023
Statut:
epublish
Résumé
Health systems need to prioritize their services, ensuring efficiency and equitable health provision allocation and access. Alongside, health technology assessment (HTA) seeks to systematically evaluate various aspects of health technologies to be used by policy- and decision-makers. In the present study, we aim to identify strengths, weaknesses, opportunities, and threats in developing an HTA in Iran. This qualitative study was conducted using 45 semi-structured interviews from September 2020 to March 2021. Participants were selected from key individuals involved in health and other health-related sectors. Based on the objectives of the study, we used purposive sampling (snowball sampling) to select individuals. The range of length of the interviews was between 45 to 75 minutes. Four authors of the present study carefully reviewed the transcripts of interviews. Meanwhile, the data were coded on the four domains of strengths, weaknesses, opportunities, and threats (SWOT). Transcribed interviews were then entered into the software and analyzed. Data management was performed using MAXQDA software, and also analyzed using directed content analysis. Participants identified eleven strengths for HTA in Iran, namely the establishment of an administrative unit for HTA within the Ministry of Health and Medical Education (MOHME); university-level courses and degrees for HTA; adapted approach of HTA models to the Iranian context; HTA is mentioned as a priority on the agenda in upstream documents and government strategic plans. On the other hand, sixteen weaknesses in developing HTA in Iran were identified: unavailability of a well-defined organizational position for using HTA graduates; HTA advantages and its basic concept are unfamiliar to many managers and decision-makers; weak inter-sectoral collaboration in HTA-related research and key stakeholders; and, failure to use HTA in primary health care. Also, participants identified opportunities for HTA development in Iran: support from the political side for reducing national health expenditures; commitment and planning to achieve universal health coverage (on behalf of the government and parliament); improved communication among all stakeholders engaged in the health system; decentralization and regionalization of decisions; and capacity building to use HTA in organizations outside the MOHME. High inflation and bad economic situation; poor transparency in decisions; lack of support from insurance companies; lack of sufficient data to conduct HTA research; rapid change of managers in the health system; and economic sanctions against Iran are threats to the developmental path of HTA in Iran. HTA can be properly developed in Iran if we use its strengths and opportunities, and address its weaknesses and threats.
Sections du résumé
BACKGROUND
Health systems need to prioritize their services, ensuring efficiency and equitable health provision allocation and access. Alongside, health technology assessment (HTA) seeks to systematically evaluate various aspects of health technologies to be used by policy- and decision-makers. In the present study, we aim to identify strengths, weaknesses, opportunities, and threats in developing an HTA in Iran.
METHOD
This qualitative study was conducted using 45 semi-structured interviews from September 2020 to March 2021. Participants were selected from key individuals involved in health and other health-related sectors. Based on the objectives of the study, we used purposive sampling (snowball sampling) to select individuals. The range of length of the interviews was between 45 to 75 minutes. Four authors of the present study carefully reviewed the transcripts of interviews. Meanwhile, the data were coded on the four domains of strengths, weaknesses, opportunities, and threats (SWOT). Transcribed interviews were then entered into the software and analyzed. Data management was performed using MAXQDA software, and also analyzed using directed content analysis.
RESULTS
Participants identified eleven strengths for HTA in Iran, namely the establishment of an administrative unit for HTA within the Ministry of Health and Medical Education (MOHME); university-level courses and degrees for HTA; adapted approach of HTA models to the Iranian context; HTA is mentioned as a priority on the agenda in upstream documents and government strategic plans. On the other hand, sixteen weaknesses in developing HTA in Iran were identified: unavailability of a well-defined organizational position for using HTA graduates; HTA advantages and its basic concept are unfamiliar to many managers and decision-makers; weak inter-sectoral collaboration in HTA-related research and key stakeholders; and, failure to use HTA in primary health care. Also, participants identified opportunities for HTA development in Iran: support from the political side for reducing national health expenditures; commitment and planning to achieve universal health coverage (on behalf of the government and parliament); improved communication among all stakeholders engaged in the health system; decentralization and regionalization of decisions; and capacity building to use HTA in organizations outside the MOHME. High inflation and bad economic situation; poor transparency in decisions; lack of support from insurance companies; lack of sufficient data to conduct HTA research; rapid change of managers in the health system; and economic sanctions against Iran are threats to the developmental path of HTA in Iran.
CONCLUSION
HTA can be properly developed in Iran if we use its strengths and opportunities, and address its weaknesses and threats.
Identifiants
pubmed: 36996128
doi: 10.1371/journal.pone.0283663
pii: PONE-D-22-12639
pmc: PMC10062657
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0283663Informations de copyright
Copyright: © 2023 Behzadifar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Global Health. 2020 Jul 8;16(1):58
pubmed: 32641066
Risk Manag Healthc Policy. 2021 Jun 28;14:2757-2770
pubmed: 34234591
Inquiry. 2020 Jan-Dec;57:46958020924920
pubmed: 32513029
Z Evid Fortbild Qual Gesundhwes. 2017 Jun;123-124:52-55
pubmed: 28549749
Health Res Policy Syst. 2018 Feb 22;16(1):15
pubmed: 29471838
Int J Technol Assess Health Care. 2005 Winter;21(1):89-95
pubmed: 15736519
Int J Technol Assess Health Care. 2020 Apr;36(2):173-178
pubmed: 32312340
Int J Technol Assess Health Care. 2017 Jan;33(4):430-433
pubmed: 28703090
Int J Technol Assess Health Care. 2020;36(1):8-11
pubmed: 31775950
Int J Technol Assess Health Care. 2020 Aug 13;:1-6
pubmed: 32787995
Int J Technol Assess Health Care. 2020;36(1):34-39
pubmed: 31928553
Health Policy. 2001 Oct;58(1):27-35
pubmed: 11518600
Value Health Reg Issues. 2021 Sep;25:126-134
pubmed: 34015521
Int J Technol Assess Health Care. 2014 Dec;30(6):587-94
pubmed: 25816824
Ther Innov Regul Sci. 2019 Jul;53(4):472-480
pubmed: 30157674
Health Res Policy Syst. 2016 May 26;14(1):38
pubmed: 27230485
BMC Health Serv Res. 2020 Mar 6;20(1):182
pubmed: 32143629
Perspect Clin Res. 2012 Apr;3(2):66-72
pubmed: 22701823
Int J Technol Assess Health Care. 2017 Jan;33(3):390-395
pubmed: 28434417
Int J Technol Assess Health Care. 2009 Jul;25 Suppl 1:260-9
pubmed: 19527545
Med J Islam Repub Iran. 2018 May 12;32:39
pubmed: 30159290
Int J Technol Assess Health Care. 2017 Jan;33(3):371-375
pubmed: 28436346
Med J Islam Repub Iran. 2016 Nov 01;30:436
pubmed: 28210601
J Prev Med Hyg. 2022 Jul 31;63(2):E351-E373
pubmed: 35968073
Int J Technol Assess Health Care. 2019;35(6):467-473
pubmed: 31190670
Cost Eff Resour Alloc. 2021 Jul 7;19(1):39
pubmed: 34233710
EGEMS (Wash DC). 2013 Oct 28;1(2):1028
pubmed: 25848573
Am J Manag Care. 2011 May;17 Suppl 5 Developing:SP53-60
pubmed: 21711078
Int J Technol Assess Health Care. 2019;35(5):393-400
pubmed: 31583985
Eur J Health Law. 2020 May 07;27(3):274-289
pubmed: 33652403
Pharmacoeconomics. 2010;28(10):831-8
pubmed: 20831290
J Med Econ. 2020 Apr;23(4):317-322
pubmed: 31944134
Int J Technol Assess Health Care. 2019 Jan;35(3):176-180
pubmed: 31006412
Health Policy. 2012 May;105(2-3):236-45
pubmed: 22364715
Int J Technol Assess Health Care. 2018 Jan;34(1):97-104
pubmed: 29151380
Int J Technol Assess Health Care. 2009 Jul;25 Suppl 1:108-11
pubmed: 19534838
J Am Coll Radiol. 2009 May;6(5):332-42
pubmed: 19394574
Health Sci Rep. 2019 Apr 14;2(6):e119
pubmed: 31236487
Health Technol Assess. 2005 May;9(20):1-92, iii-iv
pubmed: 15899148
Glob Health Action. 2017;10(1):1370194
pubmed: 29035166
EPMA J. 2010 Dec;1(4):587-94
pubmed: 23199111
Appl Health Econ Health Policy. 2017 Dec;15(6):697-706
pubmed: 28871512
Iran J Public Health. 2013 Jan 01;42(Supple1):50-4
pubmed: 23865016
Value Health Reg Issues. 2017 Dec;14:20-27
pubmed: 29254537
Iran J Public Health. 2018 Jul;47(7):1061-1062
pubmed: 30182014
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Int J Technol Assess Health Care. 2008 Spring;24(2):235-40
pubmed: 18400128
Front Public Health. 2020 Nov 26;8:561238
pubmed: 33324594
Health Policy. 2002 Feb;59(2):99-106
pubmed: 11755992
Arch Iran Med. 2021 Jan 01;24(1):58-63
pubmed: 33588569
Arch Iran Med. 2020 May 01;23(5):338-352
pubmed: 32383619
F1000Res. 2017 Dec 11;6:2119
pubmed: 29333249
J Mark Access Health Policy. 2015 Dec 09;3(1):25682
pubmed: 29785249
Int J Technol Assess Health Care. 2019;35(5):362-366
pubmed: 31506132
Appl Health Econ Health Policy. 2019 Oct;17(5):573-576
pubmed: 31161365
Health Res Policy Syst. 2014 Dec 02;12:66
pubmed: 25466570
Nurse Educ Today. 2004 Feb;24(2):105-12
pubmed: 14769454
Front Public Health. 2016 Sep 14;4:201
pubmed: 27683658
Value Health. 2015 Jun;18(4):505-11
pubmed: 26091605
Lancet. 2013 Dec 21;382(9910):e48-9
pubmed: 24360390
Lancet. 2022 Apr 23;399(10335):1625-1645
pubmed: 35397236
Int J Technol Assess Health Care. 2018 Jan;34(1):87-96
pubmed: 29455685
BMC Health Serv Res. 2020 Aug 6;20(1):722
pubmed: 32762695
Arch Iran Med. 2019 Oct 01;22(10):592-605
pubmed: 31679362
Int J Technol Assess Health Care. 2017 Jan;33(2):183-191
pubmed: 28849758
J Med Econ. 2018 May;21(5):510-517
pubmed: 29513062
Eur J Cancer Care (Engl). 2012 Jul;21(4):442-9
pubmed: 22510226
Health Policy. 2010 May;95(2-3):174-84
pubmed: 20074829
Biosci Trends. 2018;12(2):102-108
pubmed: 29760354
Int J Equity Health. 2021 Jan 14;20(1):37
pubmed: 33446202
Front Pharmacol. 2020 Feb 21;11:15
pubmed: 32153393